New inhaled drug shows promise for cystic fibrosis in early trial
NCT ID NCT06478706
First seen Jan 05, 2026 · Last updated Jun 23, 2026 · Updated 30 times
Summary
This study tested an inhaled drug called ETD001 in 57 adults with cystic fibrosis. The trial had two parts: one to check safety over 7 days, and another to see if the drug improves lung function over 28 days. Participants took the drug or a placebo twice daily. The goal is to find a new treatment that helps people with CF breathe easier.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
All Wales Adult CF Centre
Cardiff, CF64 2XX, United Kingdom
-
Azienda Ospedaliera Universitaria Integrata Verona
Verona, 37126, Italy
-
Azienda Ospedaliera Universitaria Meyer
Florence, 50139, Italy
-
Belfast Health and Social Care Trust
Belfast, BT9 7AB, United Kingdom
-
CF-Studienzentrum Universitätsklinikum Köln
Cologne, 50924, Germany
-
CHU de Montpellier
Montpellier, 34295, France
-
Charité Universtaetsmedizin
Berlin, 13353, Germany
-
Fondazione IRCCS Ca' Granda- Ospedale Maggiore Policlinico
Milan, 20122, Italy
-
Hospices Civils de Lyon
Lyon, 69495, France
-
Hôpital Cochin
Paris, 75014, France
-
Hôpitaux de Toulouse
Toulouse, 31059, France
-
IKF Pneumologie
Frankfurt, 60596, Germany
-
IRCCS Istituto Giannina Gaslini
Genova, 16147, Italy
-
LMU Kinikum
Munich, 80336, Germany
-
Ospedale Pediatrico Bambino Gesù
Roma, 00165, Italy
-
Queen Elizabeth University Hospital West of Scotland CF Service
Glasgow, G51 4TR, United Kingdom
-
Royal Brompton Hospital
London, SW3 6LL, United Kingdom
-
Royal Papworth Hospital
Cambridge, CB2 0AY, United Kingdom
-
Southampton General Hospital
Southampton, SO16 6YD, United Kingdom
-
Universitätsklinikum Frankfurt
Frankfurt, 60590, Germany
-
Westdeutsches Lungenzentrum am Universitätsklinikum
Essen, 45239, Germany
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ETD001 (inhaled drug)
What this could lead to
If successful, this could lead to a new inhaled treatment that improves lung function in people with cystic fibrosis.
What could go wrong
This is an early Phase 2 trial with only 57 participants, so results may not apply to everyone. The drug may not improve lung function or could cause side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.